Eire, thanks for taking the time to do this. Much appreciated.
My question,
Why isn't CardioCel growing faster than it is despite having the best clinical evidence in the world and many of the best surgeons in the world supporting it and so many disastrous clinical experiences with many of our main competitors? Number of cases involving CardioCel doubled in 2015 and will likely double again in 2016 although with so much to support it CardioCel should be taking market share at a much faster rate than it is. Why is it not?
AHZ Price at posting:
35.0¢ Sentiment: Buy Disclosure: Held
(20min delay)